Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study.
De Mercanti SF, Signori A, Cordioli C, Signoriello E, Lus G, Bonavita S, Abbadessa G, Lavorgna L, Maniscalco GT, Curti E, Lorefice L, Cocco E, Nociti V, Mirabella M, Baroncini D, Mataluni G, Landi D, Petruzzo M, Lanzillo R, Gandoglia I, Laroni A, Frangiamore R, Sartori A, Cavalla P, Costantini G, Capra R, Sormani MP, Clerico M. De Mercanti SF, et al. Among authors: baroncini d. J Neurol Sci. 2021 May 15;424:117385. doi: 10.1016/j.jns.2021.117385. Epub 2021 Mar 6. J Neurol Sci. 2021. PMID: 33770708
Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study.
Saccà F, Lanzillo R, Signori A, Maniscalco GT, Signoriello E, Lo Fermo S, Repice A, Annovazzi P, Baroncini D, Clerico M, Binello E, Cerqua R, Mataluni G, Bonavita S, Lavorgna L, Zarbo IR, Laroni A, Rossi S, Pareja Gutierrez L, La Gioia S, Frigeni B, Barcella V, Frau J, Cocco E, Fenu G, Torri Clerici V, Sartori A, Rasia S, Cordioli C, Di Sapio A, Pontecorvo S, Grasso R, Barrilà C, Russo CV, Esposito S, Ippolito D, Bovis F, Gallo F, Sormani MP. Saccà F, et al. Among authors: baroncini d. Mult Scler. 2019 Aug;25(9):1263-1272. doi: 10.1177/1352458518790390. Epub 2018 Jul 25. Mult Scler. 2019. PMID: 30044207 Free article.
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy.
Signoriello E, Lus G, Bonavita S, Lanzillo R, Saccà F, Landi D, Frau J, Baroncini D, Zaffaroni M, Maniscalco GT, Curti E, Sartori A, Cepparulo S, Marfia GA, Nicoletti CG, Carotenuto A, Nociti V, Caleri F, Sormani MP, Signori A. Signoriello E, et al. Among authors: baroncini d. Mult Scler. 2022 Jan;28(1):93-101. doi: 10.1177/13524585211005657. Epub 2021 Apr 15. Mult Scler. 2022. PMID: 33855897
Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study.
Frau J, Saccà F, Signori A, Baroncini D, Fenu G, Annovazzi P, Capobianco M, Signoriello E, Laroni A, La Gioia S, Sartori A, Maniscalco GT, Bonavita S, Clerico M, Russo CV, Gallo A, Lapucci C, Carotenuto A, Sormani MP, Cocco E; i-MuST study group. Frau J, et al. Among authors: baroncini d. J Neurol. 2019 Oct;266(10):2440-2446. doi: 10.1007/s00415-019-09424-8. Epub 2019 Jun 17. J Neurol. 2019. PMID: 31209573
Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?
Clerico M, De Mercanti SF, Signori A, Iudicello M, Cordioli C, Signoriello E, Lus G, Bonavita S, Lavorgna L, Maniscalco GT, Curti E, Lorefice L, Cocco E, Nociti V, Mirabella M, Baroncini D, Mataluni G, Landi D, Petruzzo M, Lanzillo R, Gandoglia I, Laroni A, Frangiamore R, Sartori A, Cavalla P, Costantini G, Sormani MP, Capra R. Clerico M, et al. Among authors: baroncini d. Neurotherapeutics. 2020 Jan;17(1):200-207. doi: 10.1007/s13311-019-00776-7. Neurotherapeutics. 2020. PMID: 31452081 Free PMC article.
First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study.
Maniscalco GT, Saccà F, Lanzillo R, Annovazzi P, Baroncini D, Binello E, Repice A, Perini P, Clerico M, Mataluni G, Bonavita S, La Gioia S, Gutierrez LP, Laroni A, Frau J, Cocco E, Torri Clerici V, Zarbo IR, Sartori A, Signoriello E, Rasia S, Cordioli C, Stromillo ML, Cerqua R, Pontecorvo S, Di Sapio A, Grasso R, Barone S, Lavorgna L, Barrilà C, Landi D, Russo CV, Frigeni B, Ippolito D, Turano G, Carmisciano L, Sormani MP, Signori A. Maniscalco GT, et al. Among authors: baroncini d. Mult Scler Relat Disord. 2020 Jul;42:102059. doi: 10.1016/j.msard.2020.102059. Epub 2020 Mar 16. Mult Scler Relat Disord. 2020. PMID: 32208344
A real-world study of alemtuzumab in a cohort of Italian patients.
Russo CV, Saccà F, Frau J, Annovazzi P, Signoriello E, Bonavita S, Grasso R, Clerico M, Cordioli C, Laroni A, Capobianco M, Torri Clerici V, Sartori A, Cavalla P, Maniscalco GT, La Gioia S, Caleri F, Giugno A, Iodice R, Carotenuto A, Cocco E, Fenu G, Zaffaroni M, Baroncini D, Lus G, Gallo A, De Mercanti SF, Lapucci C, Di Francescantonio V, Brambilla L, Sormani MP, Signori A. Russo CV, et al. Among authors: baroncini d. Eur J Neurol. 2022 Jan;29(1):257-266. doi: 10.1111/ene.15121. Epub 2021 Oct 5. Eur J Neurol. 2022. PMID: 34558755 Free PMC article.
Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study.
Baroncini D, Ghezzi A, Guaschino C, Moiola L, Filippi M, Ianniello A, Pozzilli C, Lanzillo R, Brescia-Morra V, Margoni M, Gallo P, Callari G, Grimaldi L, Lus G, Calabrese M, Simone M, Marfia GA, Rasia S, Cargnelutti D, Comi G, Zaffaroni M; MS Study Group of the Italian Neurological Society. Baroncini D, et al. Neurol Sci. 2022 Nov;43(11):6415-6423. doi: 10.1007/s10072-022-06211-8. Epub 2022 Jul 4. Neurol Sci. 2022. PMID: 35781765
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.
Prosperini L, Annovazzi P, Boffa L, Buscarinu MC, Gallo A, Matta M, Moiola L, Musu L, Perini P, Avolio C, Barcella V, Bianco A, Farina D, Ferraro E, Pontecorvo S, Granella F, Grimaldi LME, Laroni A, Lus G, Patti F, Pucci E, Pasca M, Sarchielli P; Italian Alemtuzumab Study Group. Prosperini L, et al. J Neurol. 2018 Dec;265(12):2851-2860. doi: 10.1007/s00415-018-9070-x. Epub 2018 Sep 26. J Neurol. 2018. PMID: 30259178
Cladribine vs other drugs in MS: Merging randomized trial with real-life data.
Signori A, Saccà F, Lanzillo R, Maniscalco GT, Signoriello E, Repice AM, Annovazzi P, Baroncini D, Clerico M, Binello E, Cerqua R, Mataluni G, Perini P, Bonavita S, Lavorgna L, Zarbo IR, Laroni A, Pareja-Gutierrez L, La Gioia S, Frigeni B, Barcella V, Frau J, Cocco E, Fenu G, Clerici VT, Sartori A, Rasia S, Cordioli C, Stromillo ML, Di Sapio A, Pontecorvo S, Grasso R, Barone S, Barrilà C, Russo CV, Esposito S, Ippolito D, Landi D, Visconti A, Sormani MP. Signori A, et al. Among authors: baroncini d. Neurol Neuroimmunol Neuroinflamm. 2020 Aug 14;7(6):e878. doi: 10.1212/NXI.0000000000000878. Print 2020 Nov. Neurol Neuroimmunol Neuroinflamm. 2020. PMID: 32801167 Free PMC article.
55 results